Homma Akira, Martins Reinaldo de Menezes, Leal Maria da Luz Fernandes, Freire Marcos da Silva, Couto Artur Roberto
Instituto de Tecnologia em Imunobiológicos de Bio-Manguinhos, Rio de Janeiro RJ.
Cien Saude Colet. 2011 Feb;16(2):445-58. doi: 10.1590/s1413-81232011000200008.
The smallpox worldwide eradication was the major world public health achievement. The binomial - vaccines and immunization - continues to demonstrate very high performance in the prevention and control of other diseases preventable by vaccination. The new global initiatives on vaccination, such as GAVI, have made possible the introduction of new and important vaccines preventing million of children deaths in the poorest countries in the world. The National Immunization Program of Brazil is also being strengthened, with the introduction of several new vaccines into the basic calendar as rotavirus, pneumococcal and meningococcal conjugated and H1N1 in national campaign, covering the population at risk. With the discovery of high valued vaccines, the big pharmaceutical companies became interested in this area, investing heavily in technological innovation, making fusions, acquisitions and technological partnerships. Brazil has also established a new innovation policy, creating new laws as well as subsidizing projects in technological innovation and modernization of production infra-structure.
全球根除天花是世界主要的公共卫生成就。“疫苗与免疫”这一双重手段在预防和控制其他可通过接种疫苗预防的疾病方面继续展现出卓越成效。新的全球疫苗接种倡议，如全球疫苗免疫联盟（GAVI），使得在世界最贫困国家引入新的重要疫苗成为可能，这些疫苗预防了数百万儿童死亡。巴西的国家免疫规划也在不断加强，将几种新疫苗纳入基础免疫程序，如轮状病毒疫苗、肺炎球菌结合疫苗、脑膜炎球菌结合疫苗以及甲型H1N1流感疫苗，在全国范围内开展接种活动，覆盖高危人群。随着高价值疫苗的发现，大型制药公司对该领域产生兴趣，在技术创新、并购及技术合作方面投入巨资。巴西还制定了新的创新政策，出台新法律，并为技术创新和生产基础设施现代化项目提供补贴。
